ZBIO
Zenas BioPharma, Inc. (ZBIO) Business Model Analysis (2026)
Overall Score
Revenue Model
Revenue per share remains extremely low at 0.0158 TTM, indicating a very small commercial base.
Price-to-sales is 1972.9x, implying the market is pricing in substantial future growth despite minimal current revenue.
Profitability
Gross margin is deeply negative at -59.7% TTM, showing core operations are not yet profitable.
Operating and net margins remain severely negative at -475.6% and -484.4% TTM, respectively.
Cash Generation
Free cash flow remains negative on a per-share basis at -3.58 TTM, despite a reported free cash flow to equity figure of 70.2M.
Operating cash flow is negative at -3.43 TTM, indicating the business is still consuming cash from operations.
Balance Sheet Strength
Liquidity is strong with a current ratio of 9.93x and cash ratio of 2.99x, providing a sizable near-term cushion.
Debt appears manageable relative to market value, with debt-to-market-cap at 11.3% and net debt to EBITDA near zero.
Capital Efficiency
Returns on capital remain deeply negative, with ROIC at -74.7% and ROE at -189.7% TTM.
Asset turnover is extremely low at 0.0014x, suggesting the asset base is not being converted into revenue efficiently.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Zenas BioPharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

